ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > MD&A

<< Previous

Bullboard Posts

Next >>

Comment by bball67on May 18, 2022 7:33am

143 Views

Post# 34691550

RE:RE:RE:MD&A

Promis needs to drop the comparison to Acumen which was originally to point out the disparity in market caps. The listing fee of $970k is very high. NASDAQ listing fees have apparently gone up huge. They are saying potential listing because they need to meet the criteria and the lawyers want to protect the Company.

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China